Related Experiment Video

Updated: Apr 16, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.6K

[Propranolol in infantile hemangiomas]

C Léauté-Labrèze1

  • 1Unité de dermatologie pédiatrique et centre de référence des maladies rares de la peau, hôpital Pellegrin-Enfants, CHU de Bordeaux, 33076 Bordeaux cedex, France.

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|March 11, 2015
PubMed

Insights

Propranolol is now approved for treating infantile haemangiomas (IH) in infants under 5 months. This systemic therapy requires expert initiation and monitoring due to potential risks like hypoglycemia and bronchoconstriction.

Area of Science:

  • Pediatric Dermatology
  • Pharmacology

Context:

  • Infantile haemangiomas (IH) are common vascular tumors in infants.
  • Certain IH require prompt and effective systemic treatment.
  • Propranolol offers a new therapeutic option for IH.

Purpose:

  • To outline the approved indications and administration guidelines for propranolol in treating infantile haemangiomas.
  • To inform healthcare professionals about the safe and effective use of propranolol for IH.

Summary:

  • Propranolol is indicated for infants under 5 months with IH posing life-threatening, functional, or disfigurement risks.
  • Treatment initiation requires physician expertise and a controlled clinical setting.
  • Monthly monitoring, parental education on risks (hypoglycemia, bronchoconstriction), and a 6-month treatment duration are recommended.
  • Relapses may necessitate a second course of treatment.

Impact:

  • Provides clear guidance for clinicians on propranolol use in IH.
  • Enhances patient safety through defined monitoring and risk communication.
  • Establishes a standardized approach to propranolol therapy for infantile haemangiomas.

More Related Videos

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus11:59

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus

Published on: April 28, 2023

722
Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats04:12

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats

Published on: March 28, 2025

706

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
2.0K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
622
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
2.0K